IPSEN (OTCMKTS:IPSEY) Sets New 52-Week High – Time to Buy?
by Michael Walen · The Markets DailyIPSEN (OTCMKTS:IPSEY – Get Free Report) shares reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $39.78 and last traded at $39.78, with a volume of 226 shares trading hands. The stock had previously closed at $38.45.
Analysts Set New Price Targets
Several equities research analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a report on Monday, November 3rd. UBS Group lowered shares of IPSEN from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 8th. Finally, BNP Paribas Exane lowered shares of IPSEN to an “underperform” rating in a research note on Wednesday, November 26th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, IPSEN currently has a consensus rating of “Hold”.
Get Our Latest Stock Report on IPSEN
IPSEN Stock Performance
The firm’s 50-day simple moving average is $36.34 and its 200 day simple moving average is $34.38.
About IPSEN
Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.
The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).